Towa Pharmaceutical Co., Ltd.
TWAPF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -8.07 | -0.28 | -0.22 | 0.01 |
| FCF Yield | -0.00% | 1.27% | 6.05% | -7.05% |
| EV / EBITDA | 3,207.16 | 30.81 | 33.30 | 31.22 |
| Quality | ||||
| ROIC | 0.01% | 0.80% | 1.10% | 1.43% |
| Gross Margin | 36.02% | 36.34% | 36.42% | 36.73% |
| Cash Conversion Ratio | 1.44 | 2.34 | 4.06 | -0.37 |
| Growth | ||||
| Revenue 3-Year CAGR | -3.67% | 6.34% | 7.52% | 11.98% |
| Free Cash Flow Growth | -100.10% | -86.10% | 181.80% | -415.17% |
| Safety | ||||
| Net Debt / EBITDA | 1,936.77 | 19.40 | 16.91 | 15.84 |
| Interest Coverage | 8.60 | 11.01 | 11.30 | 24.39 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.37 | 0.39 | 0.41 |
| Cash Conversion Cycle | 44,247.84 | 285.87 | 258.72 | 268.96 |